Colchicine, a neutrophil microtubule polymerization inhibitor, reduces IL-1 production and is undergoing several clinical trials for COVID-19 (NCT04322682 and 18 more) (Soy et al., 2020). The gene discussed is IL1B; the disease is COVID-19.